文献速递神经肿瘤

复发性脑膜瘤挽救性全身治疗疗效的基准设定:RANO组系统综述与荟萃分析以指导临床试验设计

Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.
PubMed 文献 · Neuro Oncol · 2025-01-01

该系统综述与荟萃分析由RANO脑膜瘤组开展,检索PubMed、ClinicalTrials.gov和ASCOpubs数据库中评估成人复发性脑膜瘤全身治疗活性的临床试验。采用随机效应模型合并6个月和1年无进展生存率(PFS-6和PFS-1年)并计算I²指数。WHO 1级复发性脑膜瘤合并PFS-6为43.6%(95%CI 22.7-67.0%,I²=80%),PFS-1年为21.7%(95%CI 6.2-53.9%,I²=76%);2-3级肿瘤PFS-6为38.0%(95%CI 28.3-48.8%,I²=68%)。作者推荐未来试验采用新的疗效基准。

要点

  • WHO 1级复发性脑膜瘤合并PFS-6为43.6%,PFS-1年为21.7%。
  • WHO 2-3级复发性脑膜瘤合并PFS-6为38.0%。
  • 靶向治疗组1级肿瘤PFS-6为62.0%、PFS-1年为49.0%。

核心结论

  • 多项研究报告了复发性脑膜瘤患者测试多种药物的结局,活性 modest 但可变且逐渐增加。
  • 在此背景下,作者推荐未来试验采用新的基准来定义未来研究性治疗的疗效。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、ClinicalTrials.gov和ASCOpubs数据库中评估成人复发性脑膜瘤全身治疗活性的临床试验。
  • 采用随机效应技术合并PFS-6和PFS-1年并计算I²指数。

主要发现

  • WHO 1级复发性脑膜瘤合并PFS-6为43.6%(95%CI:22.7-67.0%,I²=80%),PFS-1年为21.7%(95%CI:6.2-53.9%,I²=76%)。
  • WHO 2-3级复发性脑膜瘤合并PFS-6为38.0%(95%CI:28.3-48.8%,I²=68%)。
  • 靶向治疗组WHO 1级肿瘤PFS-6为62.0%(I²=58%),PFS-1年为49.0%(I²=63%)。
  • WHO 2-3级肿瘤靶向治疗PFS-6为42.1%(I²=60%),免疫治疗PFS-6为46.0%(I²=0%)。

关键数值与推荐

  • 作者设定WHO 1级肿瘤PFS-6基准为67%,PFS-1年基准为54%。
  • 作者设定WHO 2-3级肿瘤PFS-6基准为49%。

临床怎么用

  • 作者推荐未来试验采用新的基准来定义未来研究性治疗的疗效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite advances in our understanding of the molecular underpinnings of meningioma progression and innovations in systemic and local treatments, recurrent meningiomas remain a substantial therapeutic challenge. The objective of this systematic review and meta-analysis is to provide a historical baseline, contemporary analysis, and propose a "rate of probable interest" to inform future clinical trial design and development on behalf of the Response Assessment in Neuro-Oncology meningioma group. METHODS: PubMed, ClinicalTrials.gov, and ASCOpubs databases were screened for clinical trials evaluating the activity of systemic therapies for adults with recurrent meningiomas. The pooled progression-free survival at 6-months and 1-year (PFS-6 and PFS-1 year) values were calculated using the random effects technique with I2 indices. RESULTS: The pooled PFS-6 and PFS-1 year rates for recurrent WHO grade 1 meningiomas were 43.6% (95% CI: 22.7-67.0%, I2 = 80%) and 21.7% (95% CI: 6.2-53.9%, I2 = 76%), and for grades 2-3 meningiomas, the PFS-6 was 38.0% (95% CI: 28.3-48.8%, I2 = 68%). In the targeted therapy group, PFS-6 and PFS-1 year rates stood at 62.0% (I2 = 58%) and 49.0% (I2 = 63%) for grade 1, while for grades 2-3 tumors, the PFS-6 rates with targeted therapy and immunotherapy were 42.1% (I² = 60%) and 46.0% (I² = 0%), respectively. The benchmarks were set at 67% and 54% for PFS-6 and PFS-1 year for grade 1 tumors, and PFS-6 of 49% for grades 2-3 tumors. CONCLUSIONS: Several studies have reported outcomes in patients with recurrent meningiomas testing a variety of agents with modest, but variable and progressively increasing activity. In this context, we recommend new benchmarks for future trials to define efficacy of future investigational therapies.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Kotecha R, Akdemir EY, Kutuk T, et al. Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design. Neuro Oncol. 2025. PMID: 39807850. doi:10.1093/neuonc/noaf009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。